Add like
Add dislike
Add to saved papers

Protective efficacy of an inactivated chimeric H7/H5 avian influenza vaccine against highly pathogenic avian influenza H7N9 and clade 2.3.4.4 H5 viruses.

The highly pathogenic avian influenza (HPAI) H5 and H7N9 viruses pose a serious challenge to public health and the poultry industry in China. In this study, we generated a chimeric H7/H5 recombinant virus that expressed the entire HA1 region of the HPAI A/chicken/Guangdong/RZ/2017(H7N9) virus and the HA2 region of the HPAI A/chicken/Fujian/5/2016(H5N6) viruses. The resulting chimeric PR8-H7/H5 virus exhibited similar growth kinetics as the parental PR8-H5 and PR8-H7 viruses in vitro. The inactivated chimeric PR8-H7/H5 vaccine induced specific, cross-reactive hemagglutination inhibition antibodies against the H7 virus only but induced serum-neutralizing antibodies against both H7 and H5 viruses. Furthermore, the inactivated chimeric PR8-H7/H5 vaccine significantly reduced virus shedding and protected chickens from challenge with the HPAI H5N6 and H7N9 viruses. Our results suggested that the inactivated chimeric PR8-H7/H5 vaccine was effective against HPAI H5 and H7N9 viruses in chickens.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app